Agios Pharmaceuticals, Inc. AGIO

US Biotechnology

$30.65 ▼ -2.33% ($-0.73)

Open $30.97

Prev Close $31.38

Day Range $30.48 – $31.59

52W Range $22.24 – $46.00

Market Cap $1.76B

Beta 0.66

EPS (TTM) $-7.01

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2013-07-24
Shares Out.	59,700,000
Website	agios.com/ ↗
Phone	13026587581
Employees	540
Revenue	$55.4M
Gross Profit	$52.9M
Net Income	-$65.0M
Free Cash Flow	-$336.0M
Total Assets	$1.06B
Total Liabilities	$84.7M
Equity	$979.3M

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Agios Pharmaceuticals, Inc. is a publicly traded company under the ticker symbol AGIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.